Tamoxifen (Nolvadex) may interact with certain antidepressants to potentially cause cancer recurrence. Which of the following could contribute?

Tamoxifen (Nolvadex) may interact with certain antidepressants to potentially cause cancer recurrence. Which of the following could contribute?

• A. Bupropion
• B. Fluoxetine
• C. Paxil
• D. All of the Above

Answer: (D)

Tamoxifen must be metabolized by the liver enzyme CYP2D6 to form endoxifen, the active compound that effectively blocks estrogen receptors in breast tissue. When drugs inhibit CYP2D6, the formation of endoxifen drops, which can lessen tamoxifen’s anti-cancer effect and potentially increase the risk of cancer recurrence. Fluoxetine and paroxetine are among the strongest CYP2D6 inhibitors, so they can significantly reduce endoxifen levels. Bupropion also inhibits CYP2D6, contributing to the same issue. Because each of these antidepressants can interfere with tamoxifen activation, they all could contribute to diminished treatment efficacy. Clinically, this is why alternatives with little or no CYP2D6 inhibition are often preferred for patients on tamoxifen.

Tamoxifen must be metabolized by the liver enzyme CYP2D6 to form endoxifen, the active compound that effectively blocks estrogen receptors in breast tissue. When drugs inhibit CYP2D6, the formation of endoxifen drops, which can lessen tamoxifen’s anti-cancer effect and potentially increase the risk of cancer recurrence.

Fluoxetine and paroxetine are among the strongest CYP2D6 inhibitors, so they can significantly reduce endoxifen levels. Bupropion also inhibits CYP2D6, contributing to the same issue. Because each of these antidepressants can interfere with tamoxifen activation, they all could contribute to diminished treatment efficacy. Clinically, this is why alternatives with little or no CYP2D6 inhibition are often preferred for patients on tamoxifen.